May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
The Efficacy and Tolerance of Mycophenolate Mofetil for the Treatment of Uveitis
Author Affiliations & Notes
  • L. P. Schewitz
    Clinical Science at South Bristol, University of Bristol, Bristol, United Kingdom
  • S. C. Teoh
    Bristol Eye Hospital, Bristol, United Kingdom
  • A. C. Hogan
    Bristol Eye Hospital, Bristol, United Kingdom
  • A. D. Dick
    Clinical Science at South Bristol, University of Bristol, Bristol, United Kingdom
    Bristol Eye Hospital, Bristol, United Kingdom
  • R. Lee
    Clinical Science at South Bristol, University of Bristol, Bristol, United Kingdom
    Bristol Eye Hospital, Bristol, United Kingdom
  • Footnotes
    Commercial Relationships  L.P. Schewitz, None; S.C. Teoh, None; A.C. Hogan, None; A.D. Dick, None; R. Lee, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4729. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. P. Schewitz, S. C. Teoh, A. C. Hogan, A. D. Dick, R. Lee; The Efficacy and Tolerance of Mycophenolate Mofetil for the Treatment of Uveitis. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4729. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report the efficacy and tolerance of mycophenolate mofetil (MMF) for the treatment of non-infectious uveitis using the statistical methods advocated by the Standardisation of Uveitis Nomenclature (SUN) Working Group

Methods: : A pre-defined data-set was retrospectively obtained from the case-notes of 100 consecutive patients treated between April 2000 and August 2006 at a single academic referral centre and analyzed in accordance with SUN recommendations. The main outcome measures were (i) the rate of tapering oral prednisone to 10mg daily, (ii) requirement for alternative second-line immunosuppressive therapy and (iii) rate of MMF dose discontinuation due to side-effects.

Results: : In this large cohort with well-established ocular inflammation, patients successfully tapered their oral prednisone to 10mg daily at an average rate of 2.18 per patient year (PY), with an 85% probability of achieving ≤10mg after 1 year of treatment. Alternative second-line immunosuppressive therapy was introduced at a rate of 0.18/PY and MMF was discontinued due to intolerance at a rate of 0.09/PY, predominantly due to gastrointestinal upset. Rises in liver transaminases (0.09/PY) and alkaline phosphatase (0.02/PY) were also uncommon.

Keywords: uveitis-clinical/animal model • immunomodulation/immunoregulation • corticosteroids 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×